MUC1/HER2/neu peptide-based immunotherapeutic vaccines for breast adenocarcinomas. Background: For patients with breast cancer undergoing neoadjuvant systemic treatment (NST) the optimal timing of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results